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Edited by Beat ImhofAbstract The adipose-derived plasma protein, adiponectin
(APN), has various protective eﬀects on cardiovascular diseases.
In this study, we show that endogenous APN is required for full
cyclooxygenase-2 (COX-2) induction by ischemia-reperfusion
injury in the heart in vivo. In rat neonatal cardiac myocytes,
APN-induced COX-2 expression was reduced by treatment with
a sphingosine kinase-1 (SphK-1) inhibitor or siRNA targeting
SphK-1. Treatment with a sphingosine-1-phosphate (S1P) recep-
tor antagonist also diminished COX-2 expression in response to
APN stimulation. These ﬁndings suggest that APN is a physio-
logical regulator of COX-2 signaling in the heart and that this
regulation occurs in part via a SphK-1–S1P receptor dependent
mechanism in cardiac myocytes.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Obesity-related diseases are closely associated with the
development of cardiovascular diseases. Adiponectin (APN)
is a plasma protein that is primarily produced by adipose tissue
[1]. Plasma APN concentrations are decreased in association
with obesity, hypertension and ischemic heart diseases. APN
displays various protective properties in the context of obes-
ity-related metabolic, inﬂammatory and cardiovascular dis-
eases [2–6]. We have reported that APN protects the heart
from various injuries [5,7] and that it inhibits myocardial ische-
mia-reperfusion injury through both AMP-activated protein
kinase (AMPK)- and cyclooxygenase-2 (COX-2)-dependent
mechanisms [8].
COX-2, the key enzyme regulating the production of prosta-
glandins (PGs), plays a variety of roles in the cardiovascular sys-Abbreviations: APN, adiponectin; SKI, sphingosine kinase inhibitor;
APN-KO, APN-deﬁcient; WT, wild-type; SphK-1, sphingosine kinase-
1; S1P, sphingosine-1-phosphate; COX-2, cyclooxygenase-2; AMPK,
AMP-activated protein kinase; TNF-a, tumor necrosis factor-a; PG,
prostaglandin
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doi:10.1016/j.febslet.2008.03.002tem. COX inhibitors are widely used as non-steroidal anti-
inﬂammatory drugs in chronic inﬂammatory diseases [9]. How-
ever, COX-2 selective inhibitors have been associated with an
increased risk of cardiovascular events [10]. It has been reported
that COX-2 exerts cardioprotective eﬀects via the production of
PG E2 synthesis in a model of myocardial ischemia-reperfusion
injury [11]. Furthermore, we have recently reported that APN
suppresses lipopolysaccharide-induced tumor necrosis factor
(TNF)-a production in cardiac cells through COX-2–PGE2-
dependent pathways which are independent of AMPK [8].
However, the molecular mechanisms by which APN regulates
COX-2 expression in cardiac cells remain unknown.
Sphingosine-1-phosphate (S1P) is generated from sphingo-
sine through phosphorylation by sphingosine kinase (SphK)
[12]. S1P has various bioactivities, including the stimulation
of angiogenesis and the suppression of apoptosis [13]. It has
been reported that S1P increases COX-2 expression in vascular
endothelial cells [14] or smooth muscle cells [15]. These ﬁnd-
ings led us to speculate that SphK acts as a modulator for
APN–COX-2 signaling axis in cardiac myocytes. In this study,
we investigated whether APN regulates COX-2 expression
through SphK-dependent pathway.2. Materials and methods
2.1. Mouse model of myocardial ischemia-reperfusion
Wild-type (WT) and APN-deﬁcient (APN-KO) mice in C57/BL6
background were used for this study. Study protocols were approved
by the Institutional Animal Care and Use Committee in Boston Uni-
versity. Mice at the ages of 10–12 weeks were anesthetized with sodium
pentobarbital (50 mg/kg intraperitoneally). A left thoracotomy was
performed, and the left anterior descending artery (LAD) was visual-
ized under a microscope and ligated with 8-0 silk suture using snare oc-
cluder. Mice were subjected to 30 min of LAD ligation, followed by
48 h of reperfusion [8]. Mice were then sacriﬁced and the hearts were
extracted for Western blot analysis.2.2. Cell culture and treatment
Primary neonatal rat ventricular cardiac myocytes were isolated and
cultured as previously described [16]. In brief, cardiac myocytes were
treated with serum-free Dulbeccos Modiﬁed Eagle Medium (DMEM)
for 24 h prior to each experiment, and then treated with or without
human recombinant APN (30 lg/ml) for 18 h or S1P (1.0 lM) for
6 h (BIOMOL International, L.P., PA, USA). Recombinant human
APN from baculovirus-insect cell expression system was obtained
from Nosan Corp. [6]. Preincubation with 10 lM sphingosine kinaseblished by Elsevier B.V. All rights reserved.
Fig. 1. APN regulation of COX-2 in the heart and cultured cardiac
myocytes. (A) APN is required for full induction of COX-2 by
ischemia-reperfusion in heart. The expression of COX-2 protein in
heart tissues fromWT and APN-KO mice at 48 h after sham operation
or ischemia-reperfusion was analyzed by Western blotting. The
expression levels of COX-2 were quantiﬁed and expressed relative to
sham-operated WT mice. Values are expressed as means ± S.E.M.
**P < 0.01, n = 4 in each group. (B) SphK-1 inhibition reduces COX-2
induction by APN in cardiac myocytes. Cardiac myocytes were
pretreated with 10 lM SKI for 1 h prior to APN treatment. Cells were
then treated with APN (30 lg/ml) or vehicle for 18 h. Cell extracts were
analyzed in Western blotting. Values are expressed relative to the
vehicle-treated cultures and expressed as means ± S.E.M. *P < 0.01,
n = 8 in each group.
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(Avanti Polar Lipids, AL, USA), an antagonist of S1P receptors 1 and
3, or vehicle was performed for 1 h prior to APN treatment.
2.3. RNA interference experiments
The siRNA directed to SphK-1 and non-targeting siRNA control
were purchased from Dharmacon (siGENOME SMART Pool and
ON-TARGETplus siCONTROL non-targeting siRNA Pool, CO,
USA), and transfection with this agent was performed as previously re-
ported [6]. Brieﬂy, the cardiac myocytes were transfected for 24 h with
100 nM of each siRNA by using RNAiMAX reagent (Invitrogen, CA,
USA) in OptiMEM (Invitrogen) according to the manufacturers
instructions, and then medium was changed to fresh serum-free
DMEM. Experiments with cardiac myocytes transfected with siRNA
were performed 48 h later after siRNA transfection.
2.4. Measurements of the levels ofmRNA expression
Total RNA was extracted from cardiac myocytes with RNeasy mi-
cro kit (QIAGEN, CA, USA). cDNA synthesis from total RNA was
performed using a cDNA synthesis kit (QuantiTect Reverse Transcrip-
tion Kit, QIAGEN) according to the manufacturers instructions.
Transcript expression levels of SphK-1 and GAPDH were quantiﬁed
by iCycler iQ Real-Time PCR Detection Systems (BIO-RAD, CA,
USA) using SYBR Green Master Mix (Applied Biosystems, CA,
USA). Transcript levels of SphK-1 were adjusted relative to the expres-
sion of GAPDH. The sequence of PCR primer is as follows; 5 0-
GCAAGGCTCTGAAGCTCTTT-3 0 and 5 0-CCCAGTACCCAGTT-
CTTCT-30 for SphK-1 and 5 0-TCAAGAAGGTGGTGAAGCAG3 0
and 5 0-AGGTGGAAGAATGGGAGTTG-3 0 for GAPDH.
2.5. Western blotting
Protein was extracted from cardiac myocytes with cell lysis buﬀer
(Cell Signaling,MA,USA). Themethod of protein extraction frommice
hearts was previously described in detail [17]. Whole cell lysate were re-
solved on SDS–PAGE (BIO-RAD), followed by electrophoretic trans-
fer PVDF membranes (Hybond-ECL, Amersham Biosciences, NJ,
USA). Immunoreactive bandswere visualized usingECLorECL-PLUS
chemiluminescence reagent (Amersham Biosciences). The membranes
were exposed to COX-2 antibody (Cayman) and a-tubulin antibody
(Calbiochem, CA, USA), and then exposed to anti-rabbit or anti-mouse
secondary antibodies conjugated with horseradish peroxidase, respec-
tively. The band density was quantiﬁed by using Image J 1.38X
(http://rsb.info.nih.gov/ij/). All of them were normalized to a-tubulin.
2.6. Statistical analysis
Data are presented as means ± S.E.M. Statistical analysis was per-
formed by a 2-tailed Students t-test or ANOVA analysis. A value of
P < 0.05 were accepted as statistically signiﬁcant.3. Results
3.1. APN signaling is required for full COX-2 induction
following acute ischemic injury in the heart
WT and APN-KO mice underwent myocardial ischemia-
reperfusion injury or sham surgery, and COX-2 protein levels
in the heart were assessed. Little or no expression of COX-2
protein could be detected by Western blotting in hearts of
WT and APN-KO mice that had undergone sham surgery.
Ischemia-reperfusion markedly increased the expression of
COX-2 in WT mice hearts, but this upregulation was attenu-
ated in the APN-KO hearts (Fig. 1A).
3.2. APN-induced COX-2 upregulation is reduced by SphK-1
inhibition
To elucidate the mechanism of COX-2 regulation by APN,
cultured cardiac myocytes were treated with recombinant hu-
man APN. APN signiﬁcantly increased COX-2 expression in
neonatal rat cardiac myocytes [8] (Fig. 1B). To test whetherAPN augments COX-2 expression through a SphK-1-depen-
dent pathway, cardiac myocytes were pretreated with a SphK-
1 inhibitor (SKI) followed by incubation with APN or vehicle.
While no diﬀerences in COX-2 expression were observed be-
tween the presence or absence of SKI under basal conditions,
APN-induced COX-2 upregulation was diminished by 38% by
preincubationwithSKI (Fig. 1B). To corroborate these ﬁndings,
knockdown experiments were performed using siRNA against
SphK-1. SphK-1 mRNA levels were reduced by 68% by treat-
ment with siRNA for SphK-1 compared to control RNA
(Fig. 2A). Knockdown of SphK-1 suppressed APN-stimulated
COX-2 expression by 43% compared to control RNA (Fig. 2B).
3.3. APN-induced COX-2 expression is diminished by S1P
receptor antagonist
S1P acts as a ligand for S1P receptors, a family of speciﬁc-G-
protein-coupled receptors [18], and S1P receptors are ex-
pressed by cardiomyocytes [19]. Indeed, S1P upregulated
COX-2 expression in cardiac myocytes, and S1P-induced
COX-2 expression was reduced in a dose-dependent manner
by the addition of VPC23019, which antagonizes S1P receptors
1 and 3 (Fig. 3A). Thus, we assessed whether APN-induced
COX-2 upregulation is mediated by S1P receptors in cardiac
myocytes using VPC23019. Pretreatment with 0.1 and
1.0 lM, but not 0.01 lM, VPC23019 diminished APN-induced
COX-2 expression (Fig. 3B).4. Discussion
The present study demonstrates the existence of an APN–
COX-2 regulatory axis in vivo. Previously we reported that
Fig. 2. Knockdown of SphK-1 reduces COX-2 induction by APN in
cardiac myocytes. Cardiomyocytes were transfected with 100 nM
siRNA of SphK-1. (A) SphK-1 mRNA levels were reduced following
treatment with siRNA directed toward SphK-1. (B) Treatment with
siRNA against SphK-1 diminished APN-induced COX-2 upregulation
on cardiac myocytes. Forty-eight hours after siRNA transfection,
cardiac cells were treated with APN (30 lg/ml) or vehicle for 18 h.
Values are expressed relative to vehicle-treated cultures and reported as
means ± S.E.M. *P < 0.05, **P < 0.01, (A) n = 4 in each group, (B)
n = 6 in each group.
Fig. 3. S1P receptor inhibition reduces COX-2 upregulation by APN
or S1P in cardiac myocytes. (A) S1P receptor-inhibition reduces COX-
2 upregulation by S1P. Cardiac myocytes were pretreated with
VPC23019 or vehicle for 1 h prior to incubation with S1P or vehicle
for 6 h. Values are expressed relative to vehicle-treated cultures and
reported as means ± S.E.M. *P < 0.05, **P < 0.01 (A) n = 3 in each
group. (B) S1P receptor inhibition reduces COX-2 upregulation by
APN in cardiac myocytes. Cardiac myocytes were pretreated with 0.01,
0.1 and 1.0 lM VPC23019 or vehicle for 1 h prior to incubation with
APN (30 lg/ml) or vehicle for 18 h. Values are expressed relative to
vehicle-treated cultures and reported as means ± S.E.M. *P < 0.05,
**P < 0.01, n = 3–8 in each group.
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partially blocked by a COX-2 inhibitor [8]. To extend these
observations, we tested whether APN-deﬁciency would reduce
the induction of cardiac COX-2 by ischemia-reperfusion injury
in vivo. APN-KO hearts showed reduced COX-2 induction byischemia-reperfusion compared to WT hearts, indicating APN
is necessary for full COX-2 expression in the heart. These ﬁnd-
ings are of importance because they demonstrate that endoge-
nous APN participates in the myocardial COX-2 response to
injury.
This study also elucidates aspects of the mechanism by
which APN regulates COX-2 in neonatal rat cardiac myocytes.
APN-induced COX-2 expression was considerably suppressed
by incubation with SKI or siRNA of SphK-1. A S1P receptor
antagonist also repressed COX-2 upregulation by APN. These
data suggest that APN increases COX-2 expression through a
SphK-1-S1P receptor pathway. S1P is a sphingolipid metabo-
lite that regulates diverse biological processes in a variety of
cell types [20]. Whereas S1P levels are controlled by activities
of SphK-1 and SphK-2, SphK-1 is the dominant isoform in
heart tissue [21]. Deﬁciency of SphK-1 has been shown to
exaggerate cardiac cell apoptosis in oxidative stress [22] or hy-
poxia and glucose deprivation [23].
In contrast to these protective actions of SphK-1, Kase and
colleagues have recently reported that globular APN promotes
an inﬂammatory state in endothelial cells through SphK-1-
dependent NF-jB activation [24]. In contrast, others have re-
ported that APN suppresses TNF-a induced NF-jB activation
and subsequent endothelial adhesion molecules in endothelial
cells [25], and it is well established that APN has anti-inﬂam-
matory and anti-atherogenic actions [2,6].
S1P functions both as an intracellular second messenger and
an extracellular ligand of a family of ﬁve S1P receptors [26].
S1P receptors 1, 2 and 3 are expressed in adult mammalian
cardiomyocytes [27,28]. It has been reported that VPC23019,
a S1P receptors 1 and 3 antagonist, reduces the pro-survival ef-
fects of SphK-1 in cardiac cells [23]. It has also been shown
that S1P exerts protective eﬀects on cardiomyocytes survival
during hypoxia through phosphatidylinositol 3-kinase-Akt sig-
naling via S1P receptor 1 [23,28]. In this study we showed that
VPC23019 inhibited both S1P-induced and APN-induced
COX-2 upregulation in cardiac myocytes. Thus, APN may
stimulate S1P receptors via S1P production, in an autocrine
or paracrine manner, resulting in stimulation of COX-2
expression.
In summary, it is shown that APN-induced COX-2 expres-
sion in the heart is partially dependent on SphK-1. Because
COX-2 is cardioprotective, the ability of APN to stimulate
SphK-1–COX-2 signaling in cardiac myocytes may contribute
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